Navitas Pharma Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Frankfurt Germany (1986)
Status: Acquired by Gilead Sciences (2008)

Organization Overview

First Clinical Trial
2002
NCT00463450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ecron Acunova GmbH

Active Ingredients

Drugs in Phase 4 Trials (1)

epoetin (Epogen) (2 trials)

Drugs in Phase 3 Trials (2)

estradiol (progynon depot) (1 trial)

prasterone (intrarosa) (1 trial)

Drugs in Phase 2 Trials (2)

Cicletanine (1 trial)

magnesium oxide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Diabetes Mellitus (Phase 2)

Hypertension (Phase 2)

Hypokalemia (Phase 2)

Hyponatremia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 5